TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, is delighted to announce that TAP Biosystems and Merck have been nominated as co-finalists for two awards at the prestigious 2014 BioProcess International (BPI) Awards.

The nominations recognise that the ambr250™ System, developed as a result of the collaboration, is a major advance in bioprocessing technology.

At the BioProcess International Awards, TAP Biosystems and Merck have been selected as finalists in the ‘Best Collaboration Award’ and the ‘Best Technology Application — Upstream Award’ categories from amongst numerous outstanding industrial collaborations for their partnership to develop the powerful ambr250 automated mini bioreactor system.

 The high-throughput ambr250, co-developed with Merck, has the flexibility to culture mammalian lines, including CHO, or microbial cells, such as Pichia pastoris and E.coli, in single-use, stirred bioreactors utilising continuous pumped feeds. This means using the ambr250 it is now possible to fully evaluate the process characteristics of large-scale bioreactors and fermenters in weeks rather than months, making the system a significant breakthrough in bioprocessing technology.

Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems commented: “We’re honoured to be shortlisted with Merck for not one, but two BPI awards from such an amazing line-up of bioprocessing advances. Being recognised in these celebrated awards is a great accolade, and further supports the use of ambr250 technology as an excellent strategy for optimising production of antibody and protein-based therapeutics to pharma and biotech world-wide.”

more about TAP biosystems

more about the finalists